The bill outlines the authority granted to MassHealth to negotiate directly with drug manufacturers for supplemental rebate agreements, as established in July 2019. This authority has significantly expedited the process of entering into these agreements, resulting in active contracts with 27 manufacturers that yield approximately $450 million in annual savings. The report highlights the growth in the number of contracts and the financial benefits derived from value-based payment agreements, which link rebate amounts to clinical outcomes and efficacy data.

Additionally, the bill includes a detailed list of drug manufacturers and the specific drugs associated with the negotiated supplemental rebate agreements. Notable insertions in the text include the names of drugs and their initial years of contract, as well as the contact information for inquiries. This comprehensive approach aims to enhance the financial accountability of drug manufacturers while ensuring that MassHealth can provide cost-effective healthcare solutions to its beneficiaries.